// App-Quantinova.ai

AB0530 (2021) : EFFECT OF SKIN SYMPTOMS ON DISEASE IMPACT IN PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING THE IL-12/23 INHIBITOR USTEKINUMAB OR TNF INHIBITORS IN THE REAL-WORLD PSABIO STUDY

Researchers

Presenter

  • J. S. Smolen

Principal Investigators

  • T. Korotaeva

  • M. Nurmohamed

  • S. Siebert

  • P. Bergmans

  • K. De Vlam

  • E. Gremese

  • B. Joven-Ibez

  • W. Noel

  • P. Sfikakis

  • E. Theander

  • L. Gossec

Medical Centers

  • Medical University of Vienna Clinical Division of Oncology, Department of Medicine, Vienna, Austria

  • V. A. Nasonova Research Institute of Rheumatology, Spondyloarthritis and Psoriatic Arthritis, Moscow, Russian Federation

  • VU Medical Center, Department of Pathology, Amsterdam, Netherlands

  • University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow, United Kingdom

  • Janssen-Cilag BV, Biostatistics, Breda, Netherlands

  • University Hospitals Leuven, Division of Rheumatology, Leuven, Belgium

  • Catholic University of the Sacred Heart, Fondazione Policlinico A Gemelli-IRCCS, Rome, Italy

  • University Hospital De Octubre, Department of Gastroenterology, Madrid, Spain

  • Janssen Pharmaceutica NV, Medical Affairs, Beerse, Belgium

  • National and Kapodistrian University of Athens, “Laiko” General Hospital, First Department of Propaedeutic Internal Medicine, Joint Rheumatology Program, Athens, Greece

  • Janssen-Cilag AB, Medical Affairs, Solna, Sweden

  • Paris 6 University, GRC-UPMC 08, Pierre Louis Institute of Epidemiology and Public Health, Paris, France

  • Pitié-Salpêtrière Hospital, APHP, Rheumatology, Paris, France

Locations

  • Austria

  • Russia

  • Netherlands

  • United Kingdom

  • Belgium

  • Italy

  • Spain

  • Greece

  • Sweden

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • Interleukin 12

  • Tumor necrosis factor

Drug/Treatment

  • Ustekinumab

  • IL-12

Outcome

  • N/A

Study Design

  • Observational

  • Prospective

Phase

  • NA

Study Id's

  • NCT02627768

Sponsors

  • Janssen Pharmaceutical

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved